CA
NZ
UK
AU
IND
US
…
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2026-01-31 | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-01-31 | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
| Income before tax | -8.23M | -10.48M | -5.49M | -4.48M | -6.18M |
| Net income | -8.23M | -10.48M | -5.49M | -4.81M | -8.42M |
| Selling general administrative | 6.99M | 4.31M | 3.77M | 3.92M | 4.02M |
| Gross profit | 0.57M | 0.70M | 0.86M | 0.75M | 0.50M |
| Reconciled depreciation | 0.19M | 0.29M | 0.29M | 0.37M | 0.32M |
| Ebit | -8.21M | -10.46M | -5.41M | -4.15M | -3.93M |
| Ebitda | -8.01M | -10.18M | -5.12M | -3.78M | -3.61M |
| Depreciation and amortization | 0.19M | 0.29M | 0.29M | 0.37M | 0.32M |
| Operating income | -8.32M | -6.69M | -4.87M | -4.15M | -3.93M |
| Other operating expenses | 10.35M | 8.83M | 6.96M | 6.23M | 5.35M |
| Interest expense | 0.02M | 0.02M | 0.08M | 0.01M | 0.12M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 0.19M | 0.02M | - | - |
| Net interest income | -0.02M | 0.17M | -0.06M | -0.01M | -0.12M |
| Income tax expense | - | - | -0.00M | 0.33M | 2.25M |
| Total revenue | 2.04M | 2.14M | 2.09M | 2.08M | 1.42M |
| Total operating expenses | 8.88M | 7.39M | 5.73M | 4.90M | 4.43M |
| Cost of revenue | 1.47M | 1.44M | 1.22M | 1.33M | 0.92M |
| Total other income expense net | 0.09M | -3.79M | -0.61M | -0.34M | -2.25M |
| Net income from continuing ops | -8.23M | -10.48M | -5.49M | -4.48M | -6.18M |
| Net income applicable to common shares | - | - | - | -4.48M | -6.37M |
| Breakdown | 2026-01-31 | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-01-31 | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
| Total assets | 7.55M | 7.47M | 7.52M | 9.46M | 12.74M |
| Intangible assets | 0.20M | 0.26M | 0.67M | 0.78M | 0.93M |
| Other current assets | 0.18M | 0.20M | 0.21M | 0.37M | 0.37M |
| Total liab | 0.87M | 1.04M | 1.08M | 0.88M | 0.88M |
| Total stockholder equity | 6.68M | 6.43M | 6.44M | 8.57M | 11.86M |
| Other current liab | 0.50M | 0.70M | 0.68M | 0.53M | 0.64M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.02M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -46.69M | -38.46M | -27.98M | -22.49M | -18.01M |
| Good will | 1.72M | 1.72M | 5.02M | 5.02M | 5.35M |
| Cash | 4.57M | 4.31M | 0.49M | 1.99M | 4.89M |
| Total current liabilities | 0.78M | 0.98M | 1.00M | 0.75M | 0.78M |
| Current deferred revenue | 0.12M | 0.16M | 0.16M | 0.16M | 0.11M |
| Net debt | -4.33M | -4.12M | -0.25M | -1.80M | -4.76M |
| Short term debt | 0.16M | 0.13M | 0.16M | 0.05M | 0.03M |
| Short long term debt | 0.13M | 0.13M | 0.13M | 0.02M | 0.01M |
| Short long term debt total | 0.25M | 0.19M | 0.24M | 0.19M | 0.13M |
| Other stockholder equity | 53.36M | 44.88M | 34.41M | 31.06M | 29.86M |
| Property plant equipment | - | - | - | 0.96M | 1.00M |
| Total current assets | 4.99M | 4.79M | 1.02M | 2.69M | 5.47M |
| Net tangible assets | - | - | - | 2.77M | 5.58M |
| Net receivables | 0.12M | 0.07M | 0.15M | 0.11M | 0.07M |
| Long term debt | 0.04M | 0.06M | 0.08M | 0.10M | 0.10M |
| Inventory | 0.12M | 0.21M | 0.17M | 0.23M | 0.13M |
| Accounts payable | 0.50M | 0.70M | 0.68M | 0.53M | 0.64M |
| Accumulated other comprehensive income | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M |
| Non currrent assets other | - | -0.00M | - | - | - |
| Non current assets total | 2.56M | 2.68M | 6.50M | 6.76M | 7.27M |
| Capital lease obligations | 0.08M | 0.00M | 0.03M | 0.07M | 0.02M |
| Breakdown | 2026-01-31 | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-01-31 | 2025-01-31 | 2024-01-31 | 2023-01-31 | 2022-01-31 |
| Investments | - | -0.09M | -0.05M | -0.08M | -0.08M |
| Change to liabilities | - | - | - | -0.05M | -0.13M |
| Total cashflows from investing activities | -0.01M | -0.09M | -0.05M | -0.08M | -0.08M |
| Net borrowings | -0.02M | 0.28M | 2.09M | -0.02M | -1.63M |
| Total cash from financing activities | 5.40M | 8.54M | 2.09M | 0.16M | 7.63M |
| Change to operating activities | - | - | - | -0.03M | -0.38M |
| Net income | -8.23M | -10.48M | -5.49M | -4.48M | -6.18M |
| Change in cash | 0.26M | 3.82M | -1.49M | -2.91M | 4.74M |
| Begin period cash flow | 4.31M | 0.49M | 1.99M | 4.89M | 0.15M |
| End period cash flow | 4.57M | 4.31M | 0.49M | 1.99M | 4.89M |
| Total cash from operating activities | -5.13M | -4.63M | -3.53M | -2.99M | -2.81M |
| Issuance of capital stock | 5.31M | 8.41M | 0.00M | 0.00M | 6.42M |
| Depreciation | 0.19M | 0.29M | 0.29M | 0.37M | 0.32M |
| Other cashflows from investing activities | -0.01M | -0.09M | - | - | - |
| Dividends paid | - | - | - | - | -0.20M |
| Change to inventory | 0.09M | -0.04M | 0.06M | -0.10M | -0.08M |
| Change to account receivables | -0.04M | 0.07M | -0.15M | -0.04M | 0.04M |
| Sale purchase of stock | 0.00M | -0.15M | 0.00M | -0.12M | -0.10M |
| Other cashflows from financing activities | 5.40M | -8.41M | -0.00M | 0.30M | 3.14M |
| Change to netincome | - | - | - | 1.35M | 3.49M |
| Capital expenditures | 0.01M | 0.09M | 0.05M | 0.08M | 0.08M |
| Change in working capital | 0.13M | 0.03M | 0.22M | -0.22M | -0.54M |
| Stock based compensation | 0.10M | 1.54M | 0.74M | 0.73M | 1.36M |
| Other non cash items | 2.67M | 3.99M | 0.70M | 0.61M | 2.23M |
| Free cash flow | -5.13M | -4.72M | -3.58M | -3.07M | -2.89M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NTRB Nutriband Inc |
-0.12 1.87% |
6.29 | - | 370.37 | 51.25 | 15.81 | 50.06 | -4.55 |
| NVO Novo Nordisk A/S |
-0.24 0.61% |
40.20 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-21.28 3.85% |
531.87 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
12.10 1.26% |
973.36 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
| Name | Title | Year Born |
|---|---|---|
| Mr. Serguei Melnik | Founder, Pres, Company Sec. & Exec. Chairman | 1974 |
| Mr. Gareth Sheridan | Founder, CEO & Director | 1990 |
| Mr. Gerald Goodman | CFO & Chief Accounting Officer | 1948 |
| Dr. Alan Smith Ph.D. | COO & Pres of 4P Therapeutics | 1966 |
| Dr. Jeffrey Patrick Pharm.D. | Chief Scientific Officer | 1970 |
| Mr. Patrick Ryan | Chief Technical Officer | 1986 |
| Mr. Tyler Overk | Pres of Active Intelligence | 1984 |
| Mr. Serguei Melnik | Founder, President, Company Secretary & Executive Chairman of the Board | 1974 |
| Dr. Alan Smith Ph.D. | COO & President of 4P Therapeutics | 1966 |
| Mr. Tyler Overk | President of Active Intelligence | 1984 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.39%
Communication Services
+0.40%
Consumer Cyclical
-0.20%
Consumer Defensive
-0.56%
Energy
-0.45%
Financial Services
-0.09%
Financials
+0.11%
Healthcare
+0.40%
Industrials
+0.34%
Real Estate
-0.14%
Technology
+0.88%
Utilities
+0.11%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...